

ASX Announcement

5 April 2024

Cambium Bio Raises A\$3.48 Million in Strategic Placement

Key Highlights:

- Cambium Bio Limited (formerly named Regeneus Limited) (ASX:RGS) has secured firm commitments for an A\$3.48 million two-tranche Placement at A\$0.006 per share, representing a 20% premium to yesterday's closing price.
- The Placement was anchored by Orient EuroPharma, a Taiwan-listed multinational pharmaceutical company, and Zheng Yang Biomedical Technology, a cornerstone shareholder in Cambium Medical Technologies.
- Proceeds will be used to fund nonclinical studies for Elate Ocular, a novel biologic for dry eye disease, to prepare for Phase 3 trials, and for general working capital purposes.

Sydney, Australia; 5 April 2024: Cambium Bio Limited (formerly named Regeneus Limited) (ASX:RGS) (**Cambium Bio** or **Company**), a clinical-stage regenerative medicine company, is pleased to announce that it has received firm commitments from new and existing investors for a two-tranche placement to raise A\$3.48 million at A\$0.006 per share (**Placement**).

Placement Details

The Placement will result in the issuance of 580,193,928 new, ordinary, fully paid Cambium Bio shares (**New Shares**) at the offer price of A\$0.006 per New Share (**Offer Price**). The Placement was undertaken by sophisticated institutional and private investors in the healthcare and pharmaceutical biotechnology sector:

Investor	Price per New Share	Number of New Shares	Total Amount
Orient EuroPharma	A\$0.006	238,435,861	A\$1,430,615
Zheng Yang Biomedical Technology	A\$0.006	238,435,861	A\$1,430,615
Tseng, Yu-Hung (Sebastian)	A\$0.006	23,843,586	A\$143,062
Chiu, Li-Chien	A\$0.006	47,687,172	A\$286,123
Chiu, Mu-Ni	A\$0.006	31,791,448	A\$190,749
Total		580,193,928	A\$3,481,164

- Orient EuroPharma Co., Ltd. (TWO:4120 or **OEP**), headquartered in Taiwan, is a leading pharmaceutical and healthcare products company in the Asia Pacific region. With a presence in the United States, Taiwan, China, Hong Kong, Singapore, New Zealand and multiple other markets, OEP manufactures a range of therapeutics across various categories.

- Zheng Yang Biomedical Technology Co., Ltd. (**ZYBT**) is a diversified healthcare holding company based in Taiwan. ZYBT's businesses include Aventacell, Dr Wells, and a strategic minority investment in Cambium Medical Technologies, LLC (**CMT**).
- Tseng Yu-Hung (Sebastian) is the Chairman and principal shareholder of ZYBT.
- Chiu Li-Chien is the Chairman of the Taiwan-listed Hocheng Corporation (TWO:1810), a Director and a shareholder in ZYBT.

The Placement will be completed in two tranches:

Tranche	Price per New Share	Number of New Shares	Total Amount
Tranche 1	A\$0.006	153,218,457	A\$919,311
Tranche 2	A\$0.006	426,975,471	A\$2,561,853
Total		580,193,928	A\$3,481,164

Tranche 1 will be issued within Cambium Bio's existing placement capacity under ASX Listing Rules 7.1 and 7.1A. Settlement of Tranche 1 is expected to occur on 9 April 2024.

Tranche 2 is subject to Cambium Bio shareholder approvals to issue New Shares, including for the purposes of Item 7 of section 611 of the Corporations Act to approve ZYBT and Sebastian Tseng increasing their relevant interest in Cambium Bio above 20.0%. Cambium Bio will procure an Independent Expert Report (**IER**) for the shareholder meeting planned in May 2024.

Indicative Placement Timetable

- Subscription for New Shares pursuant to Tranche 1: 9 April 2024
- Dispatch of notice of meeting to Cambium Bio shareholders: 23 April 2024
- Date of shareholder meeting: 24 May 2024
- Subscription for New Shares pursuant to Tranche 2: 24 May 2024.

Use of Proceeds

The net proceeds from the Placement will be deployed to advance the development of Cambium Bio's lead product candidate, Elate Ocular, and to support the Company's broader operations. Specifically, the funds will be used to:

- Fund nonclinical studies for Elate Ocular, including the development of a potency assay and the completion of a comparability study. These activities are crucial in preparing Elate Ocular for the initiation of a pivotal Phase 3 clinical trial program.
- Prepare for the commencement of the Phase 3 registration-enabling trials for Elate Ocular in the treatment of dry eye disease, a significant unmet medical need.
- Provide additional working capital to support Cambium Bio's ongoing operations and pipeline development efforts.

By directing the proceeds towards these key priorities, Cambium Bio aims to expedite the clinical advancement of Elate Ocular and strengthen its financial position to execute on its strategic objectives.

Management Commentary

Karolis Rosickas, CEO of Cambium Bio, commented: *"The merger with CMT and the capital raise from strategic anchor healthcare investors mark a significant milestone in Regeneus' corporate history. We are delighted to partner with OEP and ZYBT to advance the development of Elate Ocular for dry eye disease through Phase 3 trials and regulatory approvals. The involvement of OEP and ZYBT will considerably enhance Cambium Bio's drug development capabilities. The substantial participation from prior CMT shareholders underscores their confidence in the potential of Elate Ocular and future clinical assets based on the fibrinogen-depleted human platelet-lysate technology."*

- ENDS -

About Cambium Bio Limited (formerly named Regeneus Ltd)

Cambium Bio Limited (formerly named Regeneus Ltd) (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio or www.regeneus.com.au.

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Cambium Bio Limited.